This certification will allow the company to accept clinical samples from most US states.
Foundation Medicine achieved Massachusetts State licensing in October 2011, enabling the company to begin processing clinical samples from most states.
The company has begun accepting clinical samples and expects to commercially launch its fully informative genomic profile for all patients with solid tumors in mid-2012.
Foundation Medicine COO Kevin Krenitsky said CLIA certification is a critical step that enables them to accept and report on clinical samples as they scale for full commercial launch later in 2012.
"Foundation Medicine has been dedicated to exceptional standards of operational performance from day one, and that quality commitment was evident in our clinical laboratory certification process," Krenitsky added.